Cited by 368Medical Imaging Techniques and ApplicationsCancer, Hypoxia, and MetabolismRadiopharmaceutical Chemistry and Applications

The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.

Metabolic Positron Emission Tomography Imaging in Cancer Detection and Therapy Response

Open access

Zhu, Aizhi, Lee, Daniel, Shim, Hyunsuk·2011·Seminars in Oncology

DOI 10.1053/j.seminoncol.2010.11.012PMC PMC3075495

Open this paper in CoChat — free account

Abstract

Positron emission tomography (PET) is a noninvasive imaging technique that provides a functional or metabolic assessment of normal tissue or disease conditions. Fluorine 18-fluorodeoxyglucose PET imaging (FDG-PET) is widely used clinically for tumor imaging due to increased glucose metabolism in most types of tumors, and has been shown to improve the diagnosis and subsequent treatment of cancers. We review its use in cancer diagnosis, staging, restaging, and assessment of response to treatment. In addition, other metabolic PET imaging agents in pre-clinical research or clinical trial stages of development are discussed, including amino acid analogs based on increased protein synthesis, and choline, which is based on increased membrane lipid synthesis. Amino acid analogs and choline are more specific to tumor cells than FDG, so they play an important role in differentiating cancers from benign conditions and in the diagnosis of cancers with low FDG uptake or high background FDG uptake. For decades, researchers have shown that tumors display altered metabolic profiles with elevated uptake of glucose, amino acids, and lipids. This can be used for cancer diagnosis and monitoring of the therapeutic response with excellent signal-to-noise ratios.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1053/j.seminoncol.2010.11.012

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Statistics, 2010
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Cancer statistics, 2009
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.
Semenza, G., Roth, P. H., Fang, H. M., & Wang, G. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31580-6 · Cited by 1,892
Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Staging of Non–Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed Tomography
Lardinois, D., Weder, W., Hany, T. F., Kamel, E. M., Korom, S., Seifert, B., von Schulthess, G. K., & Steinert, H. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022136 · Cited by 1,416
Role of amino acid transport and countertransport in nutrition and metabolism.
Christensen, H. N. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.1.43 · Cited by 1,105
c-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092
Self-citation
Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc
Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D. R., Lee, L. A., & Dang, C. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000023200 · Cited by 876
Self-citation
Clinical Applications of PET in Oncology
ROHREN, E. M., Turkington, T. G., & Coleman, R. E. (2004) · Radiology · doi:10.1148/radiol.2312021185 · Cited by 862 · cited 1×
“Although FDG-PET has shown great success in cancer diagnosis and assessment of treatment response, FDG has the following limitations: (1) increased accumulation of FDG in some benign processes, such as infectious and inflammatory lesions that can give false positive results; (2) low sensitivity in well-differentiated…”
Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines
Yanagida, O., Kanai, Y., Chairoungdua, A., Kim, D. K., Segawa, H., Nii, T., Cha, S. H., Matsuo, H., Fukushima, J.-I., Fukasawa, Y., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00384-4 · Cited by 746
Positron-emission tomography and assessment of cancer therapy.
Juweid, M., & Cheson, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050276 · Cited by 744
Tumor Mitochondria and the Bioenergetics of Cancer Cells
Pedersen, P. L. (2015) · Progress in tumor research · doi:10.1159/000401202 · Cited by 711
PET imaging of prostate cancer using carbon-11-choline.
Hara, T., Kosaka, N., & Kishi, H. (1998) · PubMed · Cited by 515
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
Som, P., Atkins, H. L., Bandoypadhyay, D., Fowler, J. S., MacGregor, R. R., Matsui, K., OSTER, Z. H., Sacker, D. F., Shiue, C., Turner, H., et al. (1980) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198012000-00045 · Cited by 504 · cited 1×
“Although FDG-PET has shown great success in cancer diagnosis and assessment of treatment response, FDG has the following limitations: (1) increased accumulation of FDG in some benign processes, such as infectious and inflammatory lesions that can give false positive results; (2) low sensitivity in well-differentiated…”
Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease
Fermé, C., Eghbali, H., Meerwaldt, J. H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., Veer, M. B. V., Walewski, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064601 · Cited by 446
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen, W., Silverman, D. H. S., Delaloye, S., Czernin, J. G., Kamdar, N. V., Pope, W. B., Satyamurthy, N., Schiepers, C. W., & Cloughesy, T. F. (2006) · PubMed · Cited by 412
PET/CT: Form and Function
Blodgett, T. M., Meltzer, C. C., & Townsend, D. W. (2007) · Radiology · doi:10.1148/radiol.2422051113 · Cited by 387 · cited 1×
“Although FDG-PET has shown great success in cancer diagnosis and assessment of treatment response, FDG has the following limitations: (1) increased accumulation of FDG in some benign processes, such as infectious and inflammatory lesions that can give false positive results; (2) low sensitivity in well-differentiated…”
FDG-PET for clinical use
Reske, S. N., & Kotzerke, J. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100626 · Cited by 366
18F-Fluorodeoxyglucose Positron Emission Tomography to Evaluate Cervical Node Metastases in Patients With Head and Neck Squamous Cell Carcinoma: A Meta-analysis
Kyzas, P., Εvangelou, Ε., Denaxa-Kyza, D., & Ioannidis, J. P. A. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn125 · Cited by 364
Head and Neck Malignancy: Is PET/CT More Accurate than PET or CT Alone?
Branstetter, B. F., Blodgett, T. M., Zimmer, L. A., Snyderman, C. H., Johnson, J. T., Raman, S., & MELTZER, C. C. (2005) · Radiology · doi:10.1148/radiol.2352040134 · Cited by 333
A unique glucose-dependent apoptotic pathway induced by c-Myc
Shim, H., Chun, Y. S., Lewis, B. C., & Dang, C. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1511 · Cited by 286
Self-citation
Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.
Schuster, D. M., Votaw, J. R., Nieh, P. T., Yu, W., Nye, J. A., Master, V. A., Bowman, F. D., Issa, M. M., & Goodman, M. M. (2007) · PubMed · Cited by 275
Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.
van Waarde, A., Cobben, D., Suurmeijer, A. J. H., Maas, B., Vaalburg, W., de Vries, E. F. J., Jager, P. L., Hoekstra, H. J., & Elsinga, P. H. (2004) · PubMed · Cited by 265
Brain tumour imaging with PET: a comparison between [ 18 F]fluorodopa and [ 11 C]methionine
Becherer, A., Karanikas, G., Szab�, M., Zettinig, G., Asenbaum, S., Marosi, C., Henk, C. B., Wunderbaldinger, P., Czech, T., Wadsak, W., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1259-1 · Cited by 264
PET imaging of brain tumor with [methyl-11C]choline.
Hara, T., Kosaka, N., Shinoura, N., & Kondo, T. (1997) · PubMed · Cited by 257
A combined PET/CT scanner: the path to true image fusion
Townsend, D. W., & Beyer, T. (2002) · British Journal of Radiology · doi:10.1259/bjr.75.suppl_9.750024 · Cited by 241 · cited 1×
“Although FDG-PET has shown great success in cancer diagnosis and assessment of treatment response, FDG has the following limitations: (1) increased accumulation of FDG in some benign processes, such as infectious and inflammatory lesions that can give false positive results; (2) low sensitivity in well-differentiated…”
Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study
Koopmans, K. P., de Vries, E. G. E., Kema, I. P., Elsinga, P. H., Neels, O. C., Sluiter, W. J., van der Horst‐Schrivers, A. N. A., & Jager, P. L. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70801-4 · Cited by 233
Clinicopathological and Prognostic Relevance of Uptake Level using 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging (18F-FDG PET/CT) in Primary Breast Cancer
Ueda, S., Tsuda, H., Asakawa, H., Shigekawa, T., Fukatsu, K., Kondo, N., Yamamoto, M., Hama, Y., Tamura, K., Ishida, J., et al. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn019 · Cited by 232
11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas
Singhal, T., Narayanan, T. K., Jain, V. K., Mukherjee, J., & Mantil, J. (2007) · Molecular Imaging and Biology · doi:10.1007/s11307-007-0115-2 · Cited by 223
Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging.
Hara, T., Kosaka, N., & Kishi, H. (2002) · PubMed · Cited by 214
Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors.
Shoup, T. M., Olson, J. J., Hoffman, J. M., Votaw, J. R., Eshima, D., Eshima, L., Camp, V. M., Stabin, M. G., Votaw, D. B., & Goodman, M. M. (1999) · PubMed · Cited by 204
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma.
Crippa, F., Leutner, M., Belli, F., Gallino, G., Gréco, M., Pilotti, S., Cascinelli, N., & Bombardieri, E. (2000) · PubMed · Cited by 192
The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.
Hicks, R. J., Kalff, V., MacManus, M. P., Ware, R. E., McKenzie, A. F., Matthews, J. P., & Ball, D. (2001) · PubMed · Cited by 191
Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
Pöpperl, G., Kreth, F. W., Herms, J. W., Koch, W., Mehrkens, J. H., Gildehaus, F. J., Kretzschmar, H. A., Tonn, J. C., & Tatsch, K. (2006) · PubMed · Cited by 189
Fluorinated amino acids for tumour imaging with positron emission tomography
Laverman, P., Boerman, O. C., Corstens, F. H. M., & Oyen, W. J. G. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-001-0716-y · Cited by 189
The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT
Beheshti, M., Vali, R., Waldenberger, P., Fitz, F., Nader, M., Hammer, J., Loidl, W. C., Pirich, C., Fogelman, I., & Langsteger, W. (2009) · Molecular Imaging and Biology · doi:10.1007/s11307-009-0217-0 · Cited by 181
Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) —Usefulness and limitations in “clinical reality”—
Higashi, T., Saga, T., Nakamoto, Y., Ishimori, T., Fujimoto, K., Doi, R., Imamura, M., & Konishi, J. (2003) · Annals of Nuclear Medicine · doi:10.1007/bf02988521 · Cited by 163
PET imaging of cellular proliferation
Mankoff, D. A., Shields, A. F., & Krohn, K. A. (2005) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2004.09.005 · Cited by 161
l ‐type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms
Kaira, K., Oriuchi, N., Imai, H., Shimizu, K., Yanagitani, N., Sunaga, N., Hisada, T., Tanaka, S., Ishizuka, T., Kanai, Y., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00969.x · Cited by 158
Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer
Al‐Ibraheem, A., Buck, A. K., Krause, B. J., Scheidhauer, K., & Schwaiger, M. (2009) · Journal of Oncology · doi:10.1155/2009/208725 · Cited by 157
Contrast-Enhanced 18F-FDG PET/CT: 1-Stop-Shop Imaging for Assessing the Resectability of Pancreatic Cancer
Strobel, K., Heinrich, S., Bhure, U., Soyka, J. D., Veit‐Haibach, P., Pestalozzi, B. C., Clavien, P., & Hany, T. F. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.051466 · Cited by 155
Role of18F-FDG PET in Assessment of Response in Non–Small Cell Lung Cancer
Hicks, R. J. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057216 · Cited by 149
Performance of integrated FDG–PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG–PET/non-contrast-enhanced CT and enhanced CT
Kitajima, K., Murakami, K., Yamasaki, E., Domeki, Y., Kaji, Y., Fukasawa, I., Inaba, N., Suganuma, N., & Sugimura, K. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0776-3 · Cited by 145
FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls
Kazama, T., Faria, S. C., Varavithya, V., Phongkitkarun, S., Ito, H., & Macapinlac, H. A. (2005) · Radiographics · doi:10.1148/rg.251045045 · Cited by 144
Fluorinated tracers for imaging cancer with positron emission tomography
Couturier, O., Luxen, A., Chatal, J.-F., Vuillez, J.-P., Rigo, P., & Hustinx, R. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1607-9 · Cited by 139
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study
the PLUS study group, Verboom, P., van Tinteren, H., Hoekstra, O. S., Smit, E. F., van den Bergh, J. H. A. M., Schreurs, A. J. M., Stallaert, R. A. L. M., Velthoven, P. C. M. V., Comans, E. F. I., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1199-9 · Cited by 137
High-Risk Melanoma: Accuracy of FDG PET/CT with Added CT Morphologic Information for Detection of Metastases
Strobel, K., Dummer, R., Husarik, D. B., Lago, M. P., Hany, T. F., & Steinert, H. C. (2007) · Radiology · doi:10.1148/radiol.2442061099 · Cited by 136
Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer
Hellwig, D., Gröschel, A., Graeter, T. P., Hellwig, A. P., Nestle, U., Schäfers, H., Sybrecht, G. W., & Kirsch, C. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1919-4 · Cited by 130
18F-FDOPA Kinetics in Brain Tumors
Schiepers, C. W., Chen, W. C., Cloughesy, T. F., Dahlbom, M. L., & Huang, S. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.039321 · Cited by 129
Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer
Ueda, S., Tsuda, H., Asakawa, H., Omata, J., Fukatsu, K., Kondo, N., Kondo, T., Hama, Y., Tamura, K., Ishida, J., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-165 · Cited by 126
18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer
Eschmann, S. M., Friedel, G., Paulsen, F., Reimold, M., Hehr, T., Budach, W., Langen, H.-J., & Bares, R. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0273-5 · Cited by 125
Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging
Ohtani, T., Kurihara, H., Ishiuchi, S., Saito, N., Oriuchi, N., Inoue, T., & Sasaki, T. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100620 · Cited by 123
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer
Sunaga, N., Oriuchi, N., Kaira, K., Yanagitani, N., Tomizawa, Y., Hisada, T., Ishizuka, T., Endo, K., & Mori, M. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.08.012 · Cited by 122
18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer
Duch, J., Fuster, D., Muñoz-Mateu, M., Fernández, P. L., Paredes, P., Fontanillas, M., Guzmán, F., Rubí, S., Lomeña, F. J., & Pons, F. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1116-y · Cited by 121
Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer
de Geus‐Oei, L., van der Heijden, E. H. F. M., Visser, E. P., Hermsen, R., van Hoorn, B. A., Timmer-Bonte, J. N. H., Willemsen, A. T. M., Pruim, J., Corstens, F. H. M., Krabbe, P. F. M., et al. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.043414 · Cited by 121
Comparative Evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for Metabolic Imaging of Low Grade Gliomas
Tripathi, M., Sharma, R., D'Souza, M. M., Jaimini, A., Panwar, P., Varshney, R., Datta, A., Kumar, N., Garg, G., Singh, D., et al. (2009) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3181becfe0 · Cited by 120
Pretreatment FDG‐PET standardized uptake value as a prognostic factor for outcome in head and neck cancer
Machtay, M. X., Natwa, M., Andrel, J. A., Hyslop, T., Anné, P. R., Lavarino, J., INTENZO, C. M., & Keane, W. M. (2008) · Head & Neck · doi:10.1002/hed.20942 · Cited by 120
Prostate Carcinoma: Diffusion-weighted Imaging as Potential Alternative to Conventional MR and C-Choline PET/CT for Detection of Bone Metastases
Luboldt, W., Küfer, R., Blumstein, N. M., Toussaint, T. L., Kluge, A., Seemann, M. D., & Luboldt, H. (2008) · Radiology · doi:10.1148/radiol.2492080038 · Cited by 119
Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors
Tian, M., Zhang, H., Oriuchi, N., Higuchi, T., & Endo, K. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1496-y · Cited by 116
FDG–PET sensitivity for melanoma lymph node metastases is dependent on tumor volume
Wagner, J. D., SCHAUWECKER, D. S., Davidson, D. D., Wenck, S., Jung, S., & Hutchins, G. D. (2001) · Journal of Surgical Oncology · doi:10.1002/jso.1102 · Cited by 116
Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography
McConathy, J., & Goodman, M. (2008) · Cancer Metastasis Review · doi:10.1007/s10555-008-9154-7 · Cited by 113
FDG-PET Imaging in Primary Bilateral Adrenal Lymphoma: A Case Report and Review of the Literature
Kumar, R., Xiu, Y., Mavi, A., El-Haddad, G. E., Zhuang, H., & Alavi, A. A. (2005) · Clinical Nuclear Medicine · doi:10.1097/01.rlu.0000155983.46815.1c · Cited by 106
Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma
Kobayashi, H., Ishii, Y., & Takayama, T. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20257 · Cited by 106
The role of FDG-PET/CT in the detection of recurrent colorectal cancer
Votrubova, J., Bělohlávek, O., Jarůšková, M., Oliverius, M., Lohynská, R., Trskova, K., Sedláčková, E., Lipská, L., & Stahalova, V. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0072-z · Cited by 105
Radiolabeled choline as a proliferation marker: Comparison with radiolabeled acetate
Yoshimoto, M., Waki, A., Obata, A., Furukawa, T., Yonekura, Y., & Fujibayashi, Y. (2004) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.05.002 · Cited by 105
Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer
Çermik, T. F., Mavi, A., Basu, S. K., & Alavi, A. A. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0580-5 · Cited by 96
Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation
Barwick, T. D., Bencherif, B., Mountz, J. M., & Avril, N. E. (2009) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32832ee93b · Cited by 93
Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma
Jiménez-Requena, F., Bolton, R. C. D., Fernández, C., Gambhir, S. S., Schwimmer, J., Pérez-Vázquez, J. M., & Carreras-Delgado, J. L. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1224-8 · Cited by 92
Carbon-11-methionine and PET is an effective method to image head and neck cancer.
Leskinen-Kallio, S., Någren, K., Lehikoinen, P., Ruotsalainen, U., Teräs, M., & Joensuu, H. (1992) · PubMed · Cited by 89
The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
Kumar, A., Kumar, R., Seenu, V., Gupta, S. D., Chawla, M., Malhotra, A., & Mehta, S. N. (2009) · European Radiology · doi:10.1007/s00330-009-1303-z · Cited by 89
The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature
Peare, R., Staff, R. T., & Heys, S. D. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0771-9 · Cited by 88
Tumor Relapse after Pancreatic Cancer Resection is Detected Earlier by 18-FDG PET than by CT
Sperti, C., Pasquali, C., Bissoli, S., Chierichetti, F., Liessi, G., & Pedrazzoli, S. (2009) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-009-1010-8 · Cited by 88
Diagnostic and Prognostic Value of 18F-FDG PET/CT for Patients with Suspected Recurrence from Squamous Cell Carcinoma of the Esophagus
Guo, H., Zhu, H. J., Xi, Y., Zhang, B., Li, L., Huang, Y., Zhang, J., Fu, Z.-M., Yang, G., Yuan, S., et al. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.036509 · Cited by 84
Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma
Juweid, M. E. (2006) · Hematology · doi:10.1182/asheducation-2006.1.259 · Cited by 83
Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients
Straver, M. E., Aukema, T. S., Olmos, R. A. V., Rutgers, E. J. T., Gilhuijs, K. G. A., Schot, M. E., Vogel, W. V., & Peeters, M.-J. T. F. D. V. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1343-2 · Cited by 78
Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract
Nakanishi, K., Ogata, S., Matsuo, H., Kanai, Y., Endou, H., Hiroi, S., Tominaga, S. O., Aida, S., Kasamatsu, H., & Kawai, T. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0457-9 · Cited by 78
Metabolic Imaging of Cerebral Gliomas: Spatial Correlation of Changes in O-(2-18F-Fluoroethyl)-l-Tyrosine PET and Proton Magnetic Resonance Spectroscopic Imaging
Stadlbauer, A., Prante, O., Nimsky, C., Salomonowitz, E. K., Buchfelder, M., Kuwert, T., Linke, R., & Ganslandt, O. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.049213 · Cited by 76
Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer
Nishiyama, Y., Yamamoto, Y., Yokoe, K., Monden, T., Sasakawa, Y., Tsutsui, K., Satoh, K., & Ohkawa, M. (2005) · Annals of Nuclear Medicine · doi:10.1007/bf02985577 · Cited by 76
FDG-PET for axillary lymph node staging in primary breast cancer
Crippa, F., Gerali, A., Alessi, A., Agresti, R., & Bombardieri, E. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1531-z · Cited by 72
18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer
Krause, B. J., Herrmann, K., Wieder, H. A., & Büschenfelde, C. M. Z. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057232 · Cited by 71
Current status of FDG‐PET for head and neck cancer
Wong, R. J. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21018 · Cited by 70
18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits.
Okuma, T., Matsuoka, T., Okamura, T., Wada, Y., Yamamoto, A., Oyama, Y., Koyama, K., Nakamura, K., Watanabe, Y., & Inoue, Y. (2006) · PubMed · Cited by 67
Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue, T., Kim, E. E., Wong, F. C., Yang, D. J., Bassa, P., Wong, W., Korkmaz, M., Tansey, W., Hicks, K., & Podoloff, D. A. (1996) · PubMed · Cited by 65
Initial Experience with the Radiotracer Anti-1-amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid (Anti-[18F]FACBC) with PET in Renal Carcinoma
Schuster, D. M., Nye, J. A., Nieh, P. T., Votaw, J. R., HALKAR, R. K., Issa, M. M., Yu, W., Sepulveda, J. N., Zeng, W., Young, A. N., et al. (2009) · Molecular Imaging and Biology · doi:10.1007/s11307-009-0220-5 · Cited by 59
Erratum to: The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT
Beheshti, M., Vali, R., Waldenberger, P., Fitz, F., Nader, M., Hammer, J., Loidl, W. C., Pirich, C., Fogelman, I., & Langsteger, W. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0327-8 · Cited by 55
Limited Predictive Value of FDG-PET for Response Assessment in the Preoperative Treatment of Esophageal Cancer: Results of a Prospective Multi-Center Trial (SAKK 75/02)
Klaeser, B., Nitzsche, E. U., Schuller, J. C., Köberle, D., Widmer, L. A., Balmer-Majno, S., Hany, T. F., Cescato-Wenger, C., Brauchli, P., Zünd, M., et al. (2009) · Onkologie · doi:10.1159/000251842 · Cited by 54
PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline.
Salem, N., Kuang, Y., Wang, F., MacLennan, G. T., & Lee, Z. (2009) · PubMed · Cited by 52
PET/CT imaging in recurrent head and neck cancer
Fukui, M. B., Blodgett, T. M., & MELTZER, C. C. (2003) · Seminars in Ultrasound CT and MRI · doi:10.1016/s0887-2171(03)90037-0 · Cited by 51
Positron emission tomographic imaging with11C-choline in differential diagnosis of head and neck tumors: comparison with18F-FDG PET
Khan, N., Oriuchi, N., Ninomiya, H., Higuchi, T., Kamada, H., & Endo, K. (2004) · Annals of Nuclear Medicine · doi:10.1007/bf02984484 · Cited by 48
Early Assessment of Therapeutic Response using FDG PET in Small Cell Lung Cancer
Yamamoto, Y., Kameyama, R., Murota, M., Bandoh, S., Ishii, T., & Nishiyama, Y. (2009) · Molecular Imaging and Biology · doi:10.1007/s11307-009-0227-y · Cited by 43
Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours
Huang, Z., Zuo, C., Guan, Y., Zhang, Z., Liu, P., Xue, F., & Lin, X. (2008) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3282f4a21e · Cited by 43
[11C]choline as a potential PET marker for imaging of breast cancer athymic mice
Zheng, Q., Stone, K. L., Mock, B. H., Miller, K. D., Fei, X., Liu, X., Wang, J.-Q., Glick‐Wilson, B. E., Sledge, G. W., & Hutchins, G. D. (2002) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(02)00339-6 · Cited by 42
The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma
Thiele, F. O., Ehmer, J., Piroth, M. D., Eble, M. J., Coenen, H. H., Kaiser, H.-J., Schaefer, W. M., Buell, U., & Boy, C. (2009) · Physics in Medicine and Biology · doi:10.1088/0031-9155/54/18/012 · Cited by 41
Bone metastasis in patients with non-small cell lung cancer: The diagnostic role of F-18 FDG PET/CT
Liu, N., Ma, L., Zhou, W., Pang, Q., Hu, M., Shi, F., Fu, Z., Li, M., Yang, G., & Yu, J. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2009.01.036 · Cited by 35
Detection of tumour invasion into the pyramidal tract in glioma patients with sensorimotor deficits by correlation of 18F-fluoroethyl-L-tyrosine PET and magnetic resonance diffusion tensor imaging
Stadlbauer, A., Pölking, E., Prante, O., Nimsky, C., Buchfelder, M., Kuwert, T., Linke, R., Doelken, M. T., & Ganslandt, O. (2009) · Acta Neurochirurgica · doi:10.1007/s00701-009-0378-2 · Cited by 34
Carbon-11-methionine PET imaging of malignant melanoma.
Lindholm, P., Leskinen, S., Någren, K., Lehikoinen, P., Ruotsalainen, U., Teräs, M., & Joensuu, H. (1995) · PubMed · Cited by 33
C-11 Choline PET/CT Imaging for Differentiating Malignant From Benign Prostate Lesions
Li, X., Liu, Q., Wang, M., Jin, X., Liu, Q., Yao, S., Liu, S., & Li, J. (2008) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e318184b3a0 · Cited by 32
Clinical Stage I Non-small Cell Lung Cancer Including FDG-PET Imaging: Sites and Time to Recurrence
Gauger, J., Patz, E. F., Coleman, R. E., & Herndon, J. E. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3180600990 · Cited by 31
Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen, Y. Y., Liang, J. A., Chen, Y. K., Tsai, C.-Y., & Kao, C. H. (2006) · PubMed · Cited by 26
Optimization of automated large-scale production of [18F]fluoroethylcholine for PET prostate cancer imaging
Pascali, G., D'Antonio, L., Bovone, P., Gerundini, P., & August, T. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.01.004 · Cited by 22
Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging
Hellwig, D., Gröschel, A., Graeter, T. P., Hellwig, A. P., Nestle, U., Schäfers, H., Sybrecht, G. W., & Kirsch, C. (2006) · Cited by 21
18F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer
Kwee, S. A., Coel, M. N., Ly, B. H., & Lim, J. (2009) · Annals of Nuclear Medicine · doi:10.1007/s12149-009-0273-1 · Cited by 20
18FDG uptake in brown fat: potential for false positives.
Evans, K. D., Tulloss, T. A., & Hall, N. W. (2007) · PubMed · Cited by 20
A quantitative review of the use of FDG-PET in the axillary staging of breast cancer.
Sloka, J. S., Hollett, P. D., & Mathews, M. (2007) · PubMed · Cited by 18
Role of FDG-PET in the diagnosis and management of lung cancer
Oyen, W. J. G., Bussink, J., Verhagen, A. F. T. M., Corstens, F. H. M., & Bootsma, G. P. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.4.561 · Cited by 16
(18)FDG-PET-scan in staging of primary malignant melanoma of the oesophagus: a case report.
Vandewoude, M. G., Cornelis, A., Wyndaele, D. N. J., Brussaard, C. C., & Kums, R. (2006) · PubMed · Cited by 16
Small Bowel Metastasis From Lung Cancer Detected on FDG PET/CT
Tülchinsky, M., Coquia, S. F., & Wagner, H. (2009) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3181a7d1fb · Cited by 15
Endotracheal Metastasis From Squamous Cell Cancer of the Head and Neck
Nguyen, B. D., Ram, P. C., & Roarke, M. C. (2008) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31816a790a · Cited by 12
Verification of Musculoskeletal FDG-PET-CT Findings Performed for Melanoma Staging
Mansour, A., Kelley, M. C., Hatmaker, A. R., Holt, G. E., & Schwartz, H. S. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0843-4 · Cited by 12
FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines
Talbot, J., Kerrou, K., Montravers, F., Nataf, V., & Chevalme, Y.-M. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0400-y · Cited by 12
Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET)
Schmid, R., Haŭtmann, H., Poellinger, B., Kellner, W., Moisseev, A., Brinkbäumer, K., WEISS, M., Hahn, K. M., & Dresel, S. H. J. (2003) · Nuclear Medicine Communications · doi:10.1097/00006231-200301000-00013 · Cited by 11
A different role for FDG PET/CT in axillary lymph node staging in breast cancer
Aukema, T. S., Straver, M. E., Olmos, R. A. V., & Vogel, W. V. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1211-0 · Cited by 9
FDG-PET/CT identifies a curable pancreatic cancer surgical tract metastasis after failure by other imaging modalities.
Lachter, J., Adler, A. C., Keidar, Z., & Haddad, R. (2008) · PubMed · Cited by 7
[Case of esophageal cancer successfully performed in early response evaluation for preoperative chemotherapy by FDG-PET].
Isa, T., KANESHIRO, T., Yamamoto, H., Nakachi, A., Teruya, T., Shiroma, H., Arakaki, K., & Nishimaki, T. (2008) · PubMed · Cited by 7
What is the role of FDG-PET in the initial staging of breast cancer?
Bělohlávek, O. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0643-7 · Cited by 5
Umbilical Metastasis From Breast Cancer Detected by FDG PET
Basely, M., Bernard, P., Gisserot, O., Maszelin, P., Bussy, E., & de Jauréguiberry, J.-P. (2009) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31819e50cb · Cited by 5
[Clinical usefulness of FDG-PET for pancreatic cancer].
Mataki, Y., Shinchi, H., Kurahara, H., Maemura, K., Noma, H., Natsugoe, S., & Takao, S. (2009) · PubMed · Cited by 4
[Early prediction of response to primary chemotherapy by sequential FDG -PET in patients with advanced breast cancer].
Momiyama, N., Ishikawa, T., Ichikawa, Y., Shimada, H., Katayama, A., & Ozawa, Y. (2007) · PubMed · Cited by 4
18F-FDG-PET zur Therapieverlaufskontrolle beim Ösophaguskarzinom
Wieder, H. A., Herrmann, K., & Krause, B. J. (2007) · Der Radiologe · doi:10.1007/s00117-006-1461-9 · Cited by 3

Sorted by citations

Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,147
“For example, it is well known from PET-scans that aggressive tumors with poor prognosis are almost always glucose/energy metabolism active tumors([203,204]).”
Background
Mass Spectrometry Imaging: A Review of Emerging Advancements and Future Insights
Buchberger, A. R., DeLaney, K., Johnson, J., & Li, L. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04733 · Cited by 1,059
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
“Despite challenges associated with targeting glucose metabolism directly, glucose uptake by cancer cells has been successfully exploited in patients through the use of the fluorodeoxyglucose positron-emission-tomography (FDG-PET) imaging to stage cancers and assess response to therapy (d’Amico, 2015; Farwell et al., 2…”
Background
Glucose transporters in cancer – from tumor cells to the tumor microenvironment
Ancey, P., Contat, C., & Meylan, E. (2018) · FEBS Journal · doi:10.1111/febs.14577 · Cited by 531
The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis
Chan, C., Li, C., Yang, W., Gao, Y., Lee, S.-W., Feng, Z., Huang, H.-Y., Tsai, K. K., Flores, L. G., Shao, Y., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.065 · Cited by 440
“diagnosis for detecting cancer cells with actively glucose uptake (Zhu et al., 2011).”

See all 368

Authors: Zhu, A., Lee, D., & Shim, H.
Affiliations: Emory University (US)
Corresponding author: Shim, Hyunsuk
ORCID: Lee, Daniel
Shim, Hyunsuk
Venue: Seminars in Oncology
Publisher: Elsevier BV
Published: 2011-02
Volume: 38
Issue: 1
Pages: 55-69
ISSN: 0093-7754 (ISSN-L)
DOI: 10.1053/j.seminoncol.2010.11.012
PMC: PMC3075495
OpenAlex: W1982620463
Cited by: 368
References: 121
Citations by year: 2026: 16 · 2025: 31 · 2024: 35 · 2023: 24 · 2022: 35 · 2021: 33 · 2020: 38 · 2019: 36 · 2018: 30 · 2017: 26 · 2016: 17 · 2015: 13 · 2014: 11 · 2013: 11 · 2012: 10
FWCI: 8.32
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Seminars in Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P50CA128301)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Keywords: FDG-PET, cancer diagnosis, tumor staging, restaging, treatment response assessment, amino acid analogs, choline PET, tumor glucose metabolism, tumor lipid metabolism, tumor imaging agents
MeSH terms: Choline, Humans, Neoplasm Staging, Neoplasms, Sensitivity and Specificity, Tyrosine, Drug Monitoring, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography, Molecular Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metabolic Positron Emission Tomography Imaging in Cancer Detection and Therapy Response

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks